<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3665999d-8433-456a-ba21-1ad35b0bd418"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold"> These highlights do not include all the information needed to use GUANFACINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for GUANFACINE EXTENDED-RELEASE TABLETS.</content>
      <br/>
      <br/>
      <br/>
      <content styleCode="bold"> GUANFACINE extended-release tablets, for oral use</content>
      <br/>
      <content styleCode="bold"> Initial U.S. Approval: 1986</content>
      <br/>
      <br/>
   </title>
   <effectiveTime value="20250331"/>
   <setId root="f4e3c976-8811-4388-92b3-d248d705f8b1"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="181620514" root="1.3.6.1.4.1.519.1"/>
            <name>Unichem Pharmaceuticals (USA), Inc.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4a2f4543-83d9-4b9b-b94d-b5bc334027f8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250331"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="29300-460" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Guanfacine</name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Guanfacine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PML56A160O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GUANFACINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="30OMY4G3MK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GUANFACINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R8WTH25YS2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DIBEHENATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="39J80LT57T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (4000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="29300-460-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250201"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA219033" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241119"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>(White to off-white)</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="7" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">41;U</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="29300-461" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Guanfacine</name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Guanfacine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="2" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PML56A160O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GUANFACINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="30OMY4G3MK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GUANFACINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R8WTH25YS2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DIBEHENATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="39J80LT57T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (4000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="29300-461-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250201"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA219033" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241119"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>(White to off-white)</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="12" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">42;U</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="29300-462" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Guanfacine</name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Guanfacine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="3" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PML56A160O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GUANFACINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="30OMY4G3MK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GUANFACINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="CQ3XH3DET6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10 ALUMINUM LAKE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J9EQA3S2JM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1 ALUMINUM LAKE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R8WTH25YS2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DIBEHENATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="39J80LT57T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (4000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="29300-462-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250201"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA219033" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241119"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GREEN">
                              <originalText>(Green to light green, slightly mottled)</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="7" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">43;U</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="29300-463" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Guanfacine</name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Guanfacine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="4" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PML56A160O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GUANFACINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="30OMY4G3MK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GUANFACINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="CQ3XH3DET6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10 ALUMINUM LAKE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J9EQA3S2JM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1 ALUMINUM LAKE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R8WTH25YS2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DIBEHENATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="39J80LT57T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (4000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="29300-463-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250201"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA219033" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241119"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GREEN">
                              <originalText>(Green to light green, slightly mottled)</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="12" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">44;U</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="d16b462d-0940-4704-9d79-a6127e59954d"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID2">Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID111">14</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230911"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID4">Guanfacine extended-release tablets are central alpha<sub>2</sub>A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications (<linkHtml href="#ID1">1</linkHtml>, <linkHtml href="#ID111">14</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID5">
               <id root="1708d6cf-70dc-43d3-8710-363d22911b07"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230911"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID24" styleCode="Disc">
                           <item>Recommended   dose: 1 mg to 7 mg (0.05-0.12 mg/kg target weight based dose range) once   daily in the morning or evening based on clinical response and tolerability (<linkHtml href="#ID8">2.2</linkHtml>).</item>
                           <item>Begin   at a dose of 1 mg once daily and adjust in increments of no more than 1 mg/week   (<linkHtml href="#ID8">2.2</linkHtml>).</item>
                           <item>Do   not crush, chew or break tablets before swallowing (<linkHtml href="#ID6">2.1).</linkHtml>
                           </item>
                           <item>Do   not administer with high-fat meals, because of increased exposure (<linkHtml href="#ID6">2.1</linkHtml>).</item>
                           <item>Do   not substitute for immediate-release guanfacine tablets on a mg-per-mg basis,   because of differing pharmacokinetic profiles (<linkHtml href="#ID12">2.3</linkHtml>).</item>
                           <item>If   switching from immediate-release guanfacine, discontinue that treatment and   titrate with guanfacine extended-release tablets as directed (<linkHtml href="#ID12">2.3</linkHtml>).</item>
                           <item>When   discontinuing, taper the dose in decrements of no more than 1 mg every 3 to 7   days to avoid rebound hypertension (<linkHtml href="#ID16">2.5</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID6">
                     <id root="a5ca5fa9-3ad1-4539-a518-ebeb370b06d6"/>
                     <title>2.1 General Instruction for Use</title>
                     <text>
                        <paragraph ID="ID7">
                           <content styleCode="underline">Swallow tablets whole. Do not crush, chew, or break tablets because this will increase the rate of guanfacine release</content>. Do not administer with high fat meals, due to increased exposure.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID8">
                     <id root="7c18352c-0ed1-460f-ad5f-dcb927a3b45e"/>
                     <title>2.2 Dose Selection</title>
                     <text>
                        <paragraph ID="ID9">Take guanfacine extended-release tablets orally once daily, either in the morning or evening, at approximately the same time each day. Begin at a dose of 1 mg/day, and adjust in increments of no more than 1 mg/week.</paragraph>
                        <paragraph>In monotherapy clinical trials, there was dose- and exposure-related clinical improvement as well as risks for several clinically significant adverse reactions (hypotension, bradycardia, sedative events). To balance the exposure-related potential benefits and risks, the recommended target dose range depending on clinical response and tolerability for guanfacine extended-release tablets is 0.05-0.12 mg/kg/day (total daily dose between 1-7 mg) (See <linkHtml href="#ID10">Table 1</linkHtml>).</paragraph>
                        <table ID="ID10" width="46%" styleCode="Noautorules">
                           <caption/>
                           <col width="30%"/>
                           <col width="70%"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Table 1: Recommended Target Dose Range for Therapy with Guanfacine Extended-Release Tablets</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Weight</content>
                                    <br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Target dose range (0.05 - 0.12 mg/kg/day)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="center"> 25-33.9 kg<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center"> 2-3 mg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="center"> 34-41.4 kg<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center"> 2-4 mg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="center"> 41.5-49.4 kg<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center"> 3-5 mg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="center"> 49.5-58.4 kg<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center"> 3-6 mg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Lrule Botrule Rrule" align="center"> 58.5-91 kg<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center"> 4-7 mg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="center"> &gt;91 kg<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="center"> 5-7 mg/day<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Lrule Botrule Rrule" align="left"> Doses above 4 mg/day have not been evaluated in children (ages 6-12 years) and doses above 7 mg/day have not been evaluated in adolescents (ages 13-17 years)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID11">In the adjunctive trial which evaluated guanfacine extended-release tablets treatment with psychostimulants, the majority of patients reached optimal doses in the 0.05-0.12 mg/kg/day range. Doses above 4 mg/day have not been studied in adjunctive trials.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID12">
                     <id root="c670a8b0-cc8c-416e-b6eb-c802db4ce6a3"/>
                     <title>2.3 Switching from Immediate-Release Guanfacine to Guanfacine Extended-Release Tablets</title>
                     <text>
                        <paragraph ID="ID13">If switching from immediate-release guanfacine, discontinue that treatment, and titrate with guanfacine extended-release tablets following above recommended schedule.</paragraph>
                        <paragraph>Do not substitute for immediate-release guanfacine tablets on a milligram-per-milligram basis, because of differing pharmacokinetic profiles. Guanfacine extended-release tablets have significantly reduced C<sub>max</sub> (60% lower), bioavailability (43% lower), and a delayed T<sub>max</sub> (3 hours later) compared to those of the same dose of immediate-release guanfacine [<content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#ID100">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID14">
                     <id root="1dbabf37-9608-4d38-9071-7d6d6037956f"/>
                     <title>2.4 Maintenance Treatment</title>
                     <text>
                        <paragraph ID="ID15">Pharmacological treatment of ADHD may be needed for extended periods. Healthcare providers should periodically re-evaluate the long-term use of guanfacine extended-release tablets, and adjust weight-based dosage as needed. The majority of children and adolescents reach optimal doses in the 0.05-0.12 mg/kg/day range. Doses above 4 mg/day have not been evaluated in children (ages 6-12 years) and above 7 mg/day have not been evaluated in adolescents (ages 13-17 years) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID111">14</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID16">
                     <id root="3a0c1541-5f7a-48d1-8e9e-6001b934f435"/>
                     <title>2.5 Discontinuation of Treatment</title>
                     <text>
                        <paragraph ID="ID17">Following discontinuation of guanfacine extended-release tablets, patients may experience increases in blood pressure and heart rate [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#ID40">5.4</linkHtml>) and Adverse Reactions (<linkHtml href="#ID44">6</linkHtml>)</content>]. Patients/caregivers should be instructed not to discontinue guanfacine extended-release tablets without consulting their health care provider. Monitor blood pressure and pulse when reducing the dose or discontinuing the drug. Taper the daily dose in decrements of no more than 1 mg every 3 to 7 days to minimize the risk of rebound hypertension.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID18">
                     <id root="978b69c1-1dfc-44f1-b6a8-2edf02bf22fa"/>
                     <title>2.6 Missed Doses</title>
                     <text>
                        <paragraph ID="ID19">When reinitiating patients to the previous maintenance dose after two or more missed consecutive doses, consider titration based on patient tolerability.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID20">
                     <id root="89b28c9e-ffa7-4914-a2ad-1032c148520c"/>
                     <title>2.7 Dosage Adjustment with Concomitant Use of Strong and Moderate CYP3A4 Inhibitors or Inducers</title>
                     <text>
                        <paragraph ID="ID21">Dosage adjustments for guanfacine extended-release tablets are recommended with concomitant use of strong and moderate CYP3A4 inhibitors (e.g., ketoconazole), or CYP3A4 inducers (e.g., carbamazepine) (<linkHtml href="#ID22">Table 2</linkHtml>) <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID68">7</linkHtml>)].</content>
                        </paragraph>
                        <table ID="ID22" width="50%" styleCode="Noautorules">
                           <caption>  Table 2: Guanfacine Extended-Release Tablets Dosage Adjustments for Patients Taking Concomitant CYP3A4 Inhibitors or Inducers </caption>
                           <col width="10%"/>
                           <col width="27%"/>
                           <col width="31%"/>
                           <col width="30%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td colspan="3" valign="bottom" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Clinical Scenarios</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Starting guanfacine extended-release tablets while currently on a CYP3A4 modulator</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Continuing guanfacine extended-release tablets while adding a CYP3A4 modulator</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Continuing guanfacine extended-release tablets while stopping a CYP3A4 modulator</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> CYP3A4</content>
                                    <br/>
                                    <content styleCode="bold"> Strong and moderate Inhibitors</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Decrease</content>  guanfacine extended-release tablets dosage to half the recommended level. <br/> (see <linkHtml href="#ID10">Table 1</linkHtml>)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Decrease</content>  guanfacine extended-release tablets dosage to half the recommended level. <br/> (see <linkHtml href="#ID10">Table 1</linkHtml>)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Increase</content>  guanfacine extended-release tablets dosage to recommended level. <br/> (see <linkHtml href="#ID10">Table 1</linkHtml>)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> CYP3A4</content>
                                    <br/>
                                    <content styleCode="bold"> Strong and moderate Inducers</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Consider increasing</content>  guanfacine extended-release tablets dosage up to double the recommended level. <br/> (see <linkHtml href="#ID10">Table 1</linkHtml>)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Consider increasing</content>  guanfacine extended-release tablets dosage up to double the recommended level over 1 to 2 weeks. (see <linkHtml href="#ID10">Table 1</linkHtml>)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Decrease</content>  guanfacine extended-release tablets dosage to recommended level over 1 to 2 weeks. (see <linkHtml href="#ID10">Table 1</linkHtml>)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID25">
               <id root="6a89e1b6-019e-48f0-98e2-cff592d5944e"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID26">1 mg, 2 mg, 3   mg and 4 mg extended-release tablets.</paragraph>
               </text>
               <effectiveTime value="20230911"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID28">Extended-release tablets: 1 mg, 2 mg, 3 mg and 4 mg.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID29">
               <id root="e536bf13-e231-40b7-bb74-73a1a34b9aa9"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID30">Guanfacine extended-release tablets are contraindicated in   patients with a history of a hypersensitivity reaction to guanfacine   extended-release tablets or its inactive ingredients, or other products   containing guanfacine. Rash and pruritus have been reported.</paragraph>
               </text>
               <effectiveTime value="20230911"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID32">History of hypersensitivity to guanfacine   extended-release tablets, its inactive ingredients, or other products containing guanfacine. </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID33">
               <id root="a0815a19-1548-4638-b7f1-dfae44bd7d5f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230911"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID43" styleCode="Disc">
                           <item>Hypotension, bradycardia, syncope: Titrate slowly and monitor   vital signs frequently in patients at risk for hypotension, heart block,   bradycardia, syncope, cardiovascular disease, vascular disease,   cerebrovascular disease or chronic renal failure. Measure heart rate and   blood pressure prior to initiation of therapy, following dose increases, and   periodically while on therapy. Avoid concomitant use of drugs with additive   effects unless clinically indicated. Advise patients to avoid becoming   dehydrated or overheated (<linkHtml href="#ID34">5.1</linkHtml>).</item>
                           <item>Sedation and somnolence: Occur commonly with   guanfacine extended-release tablets Consider the potential   for additive sedative effects with CNS   depressant drugs. Caution patients against operating heavy equipment   or driving until they know how they respond to guanfacine   extended-release tablets   (<linkHtml href="#ID36">5.2</linkHtml>).</item>
                           <item>Cardiac Conduction Abnormalities: May   worsen sinus node dysfunction and atrioventricular   (AV) block, especially in patients   taking other sympatholytic   drugs. Titrate slowly and monitor vital   signs frequently (<linkHtml href="#ID38">5.3</linkHtml>).</item>
                           <item>Rebound Hypertension: Abrupt   discontinuation of guanfacine extended-release tablets can lead to clinically significant   and persistent rebound hypertension.   Subsequent hypertensive encephalopathy was also reported. To minimize the risk of rebound hypertension upon discontinuation,   the total daily dose of guanfacine   extended-release tablets   should be tapered in decrements of   no more than 1 mg every 3 to 7   days (<linkHtml href="#ID40">5.4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID34">
                     <id root="c00078cd-c2f6-4d76-89d9-7f6ae13fbbc0"/>
                     <title>5.1 Hypotension, Bradycardia, and Syncope</title>
                     <text>
                        <paragraph ID="ID35">Treatment with guanfacine extended-release tablets can cause   dose-dependent decreases in blood pressure and heart rate. Decreases were   less pronounced over time of treatment. Orthostatic hypotension and syncope   have been reported [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#ID46">6.1</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Measure heart rate and blood pressure prior to initiation of   therapy, following dose increases, and periodically while on therapy. Titrate   guanfacine extended-release tablets slowly in patients with a history of   hypotension, and those with underlying conditions that may be worsened by   hypotension and bradycardia; e.g., heart block, bradycardia, cardiovascular   disease, vascular disease, cerebrovascular disease, or chronic renal failure.   In patients who have a history of syncope or may have a condition that   predisposes them to syncope, such as hypotension, orthostatic hypotension,   bradycardia, or dehydration, advise patients to avoid becoming dehydrated or   overheated. Monitor blood pressure and heart rate, and adjust dosages   accordingly in patients treated concomitantly with antihypertensive or other   drugs that can reduce blood pressure or heart rate or increase the risk of   syncope.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID36">
                     <id root="309ed0c5-1dd9-43be-b4b9-f4880240f05b"/>
                     <title>5.2 Sedation and Somnolence</title>
                     <text>
                        <paragraph ID="ID37">Somnolence and sedation were commonly reported adverse reactions   in clinical <content styleCode="italics">studies [see Adverse Reactions (<linkHtml href="#ID46">6.1</linkHtml>)].</content>   Before using guanfacine extended-release tablets with other centrally active   depressants, consider the potential for additive sedative effects. Caution   patients against operating heavy equipment or driving until they know how   they respond to treatment with guanfacine extended-release tablets. Advise   patients to avoid use with alcohol.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID38">
                     <id root="900e2069-593b-40b0-8875-3e031646eb2b"/>
                     <title>5.3 Cardiac Conduction Abnormalities</title>
                     <text>
                        <paragraph ID="ID39">The sympatholytic action of guanfacine extended-release tablets   may worsen sinus node dysfunction and atrioventricular (AV) block, especially   in patients taking other sympatholytic drugs. Titrate guanfacine   extended-release tablets slowly and monitor vital signs frequently in   patients with cardiac conduction abnormalities or patients concomitantly   treated with other sympatholytic drugs.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID40">
                     <id root="89daadaf-5c41-47a7-8e49-b6797eb94644"/>
                     <title>5.4 Rebound Hypertension</title>
                     <text>
                        <paragraph ID="ID41">In post marketing experience, abrupt discontinuation of guanfacine   extended-release tablets has resulted in clinically significant and   persistent rebound hypertension above baseline levels and increases in heart   rate. Hypertensive encephalopathy has also been reported in association with   rebound hypertension with both guanfacine extended-release tablets and   immediate release guanfacine <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID64">6.2</linkHtml>)].   </content>In these cases, high-dosage guanfacine was discontinued; concomitant   stimulant use was also reported, which may potentially increase hypertensive   response upon abrupt discontinuation of guanfacine. Children commonly have   gastrointestinal illnesses that lead to vomiting, and a resulting inability   to take medications, so they may be especially at risk for rebound   hypertension.</paragraph>
                        <paragraph>To minimize the risk of rebound hypertension upon discontinuation,   the total daily dose of guanfacine  extended-release tablets should be   tapered in decrements of no more than 1 mg every 3 to 7 days <content styleCode="italics">[see Dosage   and Administration (<linkHtml href="#ID16">2.5</linkHtml>)].</content> Blood pressure and   heart rate should be monitored when reducing the dose or discontinuing   guanfacine extended-release tablets. If abrupt discontinuation occurs   (especially with concomitant stimulant use), patients should be closely   followed for rebound hypertension.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID44">
               <id root="cc058768-ac83-424f-a29d-4dc818a79c58"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID45">The following   serious adverse reactions are described elsewhere in the labeling:</paragraph>
                  <paragraph>•    Hypotension, bradycardia, and syncope [<content styleCode="italics">see Warnings and   Precautions (<linkHtml href="#ID34">5.1</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>•    Sedation and somnolence <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID36">5.2</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>•    Cardiac conduction abnormalities <content styleCode="italics">[see Warnings and   Precautions (<linkHtml href="#ID38">5.3</linkHtml>)]</content>
                  </paragraph>
                  <paragraph>•    Rebound Hypertension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID40">5.4</linkHtml>)]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230911"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID67">Most common adverse reactions (≥5% and at least twice   placebo rate) in fixed-dose monotherapy ADHD trials in children and   adolescents (6 to  17 years): hypotension, somnolence, fatigue, nausea, and   lethargy (<linkHtml href="#ID46">6.1</linkHtml>) </paragraph>
                        <paragraph>Flexible dose-optimization ADHD trials in children (6 to 12 years)   and adolescents (13 to 17 years): somnolence, hypotension, abdominal pain,   insomnia, fatigue, dizziness, dry mouth, irritability, nausea, vomiting, and   bradycardia (<linkHtml href="#ID46">6.1</linkHtml>). </paragraph>
                        <paragraph>Adjunctive treatment to psychostimulant ADHD trial in children and   adolescents (6 to 17 years): somnolence, fatigue, insomnia, dizziness, and   abdominal pain (<linkHtml href="#ID46">6.1</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Unichem   Pharmaceuticals (USA) Inc. at 1-866-562-4616 or FDA at 1-800-FDA-1088 or   www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID46">
                     <id root="a02891fe-abe8-4172-b3e8-98c8d16b5b38"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID47">Because clinical trials are conducted under widely varying   conditions, adverse reaction rates observed in the clinical trials of a drug   cannot be directly compared to rates in the clinical trials of another drug   and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The data described below reflect clinical trial exposure to   guanfacine extended-release tablets in 2,825 patients. This includes 2,330   patients from completed studies in children and adolescents, ages 6 to 17   years and 495 patients in completed studies in adult healthy volunteers.</paragraph>
                        <paragraph>The mean duration of exposure of 446 patients that previously   participated in two 2-year, open-label long-term studies was approximately 10   months.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Fixed Dose   Trials</content>
                        </paragraph>
                        <table ID="ID123" width="630" styleCode="Noautorules">
                           <caption/>
                           <col width="141"/>
                           <col width="66"/>
                           <col width="63"/>
                           <col width="74"/>
                           <col width="84"/>
                           <col width="78"/>
                           <col width="123"/>
                           <tbody>
                              <tr>
                                 <td colspan="7" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Table 3:  Percentage of Patients Experiencing Most Common (≥5% and at least twice the rate for placebo) Adverse Reactions in Fixed Dose Studies 1 and 2</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td colspan="5" valign="bottom" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Guanfacine Extended-Release Tablets (mg)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center">
                                    <br/>
                                    <content styleCode="bold"> Adverse Reaction</content>
                                    <br/>
                                    <content styleCode="bold">            Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <content styleCode="bold"> (N=149)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 1mg* (N=61)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 2mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N=150)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 3mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N=151)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 4mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N=151)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> All Doses of Guanfacine Extended-Release Tablets</content>
                                    <br/>
                                    <content styleCode="bold"> (N=513)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Somnolence<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 11%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 28%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 30%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 38%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 51%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 38%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Fatigue<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 17%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 15%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 14%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hypotension<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dizziness<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Lethargy<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Nausea<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dry mouth<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" valign="top" styleCode="Lrule Botrule Rrule" align="left"> *The lowest dose of 1 mg used in Study 2 was not randomized to patients weighing more than 50 kg. <br/> a: The somnolence term includes somnolence, sedation, and hypersomnia.<br/> b: The hypotension term includes hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased).<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID138" width="624" styleCode="Noautorules">
                           <caption/>
                           <col width="142"/>
                           <col width="72"/>
                           <col width="72"/>
                           <col width="78"/>
                           <col width="84"/>
                           <col width="78"/>
                           <col width="98"/>
                           <tbody>
                              <tr>
                                 <td colspan="7" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Table 4: Adverse Reactions Leading to Discontinuation (≥2% for all doses of Guanfacine Extended-Release Tablets and &gt;rate than in placebo) in Fixed Dose Studies 1 and 2</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td colspan="5" valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Guanfacine Extended-Release Tablets (mg)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Adverse Reaction</content>
                                    <br/>
                                    <content styleCode="bold"> Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <content styleCode="bold"> (N=149)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 1mg* (N=61)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 2mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N=150)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 3mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N=151)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 4mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N=151)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> All Doses of Guanfacine Extended-Release Tablets (N=513)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule" align="center"> n(%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> n(%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> n (%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> n (%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> n(%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> n(%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Total patients<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4 (3%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2(3%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10 (7%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 15 (10%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 27 (18%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 54 (11%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Somnolence<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1(1%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2(3%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5(3%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6 (4%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 17 (11%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 30(6%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Fatigue<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2(1%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2 (1%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4(3%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8(2%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Adverse reactions leading to discontinuation in ≥2% in any dose group but did not meet this criteria in all doses combined: hypotension (hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased), headache, and dizziness.<br/> * The lowest dose of 1 mg used in Study 2 was not randomized to patients weighing more than 50 kg. <br/> a: The somnolence term includes somnolence, sedation, and hypersomnia.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID125" width="635" styleCode="Noautorules">
                           <caption/>
                           <col width="129"/>
                           <col width="62"/>
                           <col width="71"/>
                           <col width="59"/>
                           <col width="67"/>
                           <col width="79"/>
                           <col width="167"/>
                           <tbody>
                              <tr>
                                 <td colspan="7" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Table 5: Other Common Adverse Reactions (≥2% for all doses of Guanfacine Extended-Release Tablets and &gt;rate than in placebo) in Fixed Dose Studies 1 and 2</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                                 <td colspan="5" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Guanfacine Extended-Release Tablets (mg)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Adverse Reaction</content>
                                    <br/>
                                    <content styleCode="bold"> Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <content styleCode="bold"> (N=149)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 1mg* (N=61)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 2mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N=150)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 3mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N=151)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> 4mg</content>
                                    <br/>
                                    <content styleCode="bold"> (N=151)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> All Doses of Guanfacine Extended-Release Tablets </content>
                                    <br/>
                                    <content styleCode="bold"> (N=513)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Headache<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 19%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 26%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 25%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 16%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 28%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 23%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Abdominal Pain<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 9%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 11%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 15%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 11%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Decreased Appetite<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 9%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Irritability<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Constipation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Nightmare<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Enuresis<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Affect Lability<sup>d</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Adverse reactions ≥2% for all doses of guanfacine extended-release tablets and &gt;rate in placebo in any dose group but did not meet this criteria in all doses combined: insomnia (insomnia, initial insomnia, middle insomnia, terminal insomnia, sleep disorder), vomiting, diarrhea, abdominal/stomach discomfort (abdominal discomfort, epigastric discomfort, stomach discomfort), rash (rash, rash generalized, rash papular), dyspepsia, increased weight, bradycardia (bradycardia, sinus bradycardia), asthma (asthma, bronchospasm, wheezing), agitation, anxiety (anxiety, nervousness), sinus arrhythmia, blood pressure increased (blood pressure increased, blood pressure diastolic increased), and first degree atrioventricular block.<br/> * The lowest dose of 1 mg used in Study 2 was not randomized to patients weighing more than 50 kg.<br/> a: The abdominal pain term includes abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.<br/> b: The nightmare term includes abnormal dreams, nightmare, and sleep terror. <br/> c: The enuresis term includes enuresis, nocturia, and urinary incontinence.<br/> d: The affect lability term includes affect lability and mood swings.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID51">
                           <content styleCode="underline">Monotherapy   Flexible Dose Trials</content>
                        </paragraph>
                        <table ID="ID126" width="623" styleCode="Noautorules">
                           <caption/>
                           <col width="235"/>
                           <col width="97"/>
                           <col width="92"/>
                           <col width="93"/>
                           <col width="106"/>
                           <tbody>
                              <tr>
                                 <td colspan="5" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Table 6:  Percentage of Patients Experiencing Most Common (≥5% and at least twice the rate for</content>
                                    <br/>
                                    <content styleCode="bold"> placebo) Adverse Reactions in the Monotherapy Flexible Dose Study 4</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td colspan="3" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Guanfacine  Extended-Release Tablets</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Adverse Reaction Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <content styleCode="bold"> (N=112)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> AM </content>
                                    <br/>
                                    <content styleCode="bold"> (N=107)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> PM </content>
                                    <br/>
                                    <content styleCode="bold"> (N=114)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> All Doses of Guanfacine Extended-Release Tablets</content>
                                    <br/>
                                    <content styleCode="bold">  (N=221)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Somnolence<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 15%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 57%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 54%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 56%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Abdominal Pain<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 19%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 14%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Fatigue<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 11%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 11%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Irritability<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Nausea<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dizziness<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Vomiting<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hypotension<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Decreased Appetite<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Enuresis<sup>d</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"> a: The somnolence term includes somnolence, sedation, and hypersomnia.<br/> b: The abdominal pain term includes abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness<br/> c: The hypotension term includes hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased).<br/> d: The enuresis term includes enuresis, nocturia, and urinary incontinence.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID128" width="623" styleCode="Noautorules">
                           <caption/>
                           <col width="141"/>
                           <col width="102"/>
                           <col width="108"/>
                           <col width="108"/>
                           <col width="164"/>
                           <tbody>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Table 7:  Adverse Reactions Leading to Discontinuation (≥2% for all doses of Guanfacine Extended-Release Tablets and &gt;rate than in placebo) in Monotherapy Flexible Dose Study 4</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/>
                                 </td>
                                 <td colspan="3" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Guanfacine Extended-Release Tablets</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Adverse Reaction</content>
                                    <br/>
                                    <content styleCode="bold"> Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <content styleCode="bold"> (N=112)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> AM </content>
                                    <br/>
                                    <content styleCode="bold"> (N=107)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> PM </content>
                                    <br/>
                                    <content styleCode="bold"> (N=114)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> All Doses of Guanfacine Extended-Release Tablets (N=221)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule" align="center"> n (%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> n (%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> n (%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> n (%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Total patients<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8(7%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7 (6%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 15(7%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Somnolence<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4(4%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3 (3%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7(3%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Adverse reactions leading to discontinuation in ≥2% in any dose group but did not meet this criteria in all doses combined: fatigue<br/> a: The somnolence term includes somnolence, sedation, and hypersomnia.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID127" width="623" styleCode="Noautorules">
                           <caption/>
                           <col width="142"/>
                           <col width="91"/>
                           <col width="114"/>
                           <col width="108"/>
                           <col width="169"/>
                           <tbody>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Table 8:  Other Common Adverse Reactions (≥2% for all doses of Guanfacine  Extended-Release Tablets and &gt;rate than in placebo) in the Monotherapy Flexible Dose Study 4</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td colspan="3" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Guanfacine  Extended-Release Tablets</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Adverse Reaction</content>
                                    <br/>
                                    <content styleCode="bold"> Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <content styleCode="bold"> (N=112)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> AM </content>
                                    <br/>
                                    <content styleCode="bold"> (N=107)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> PM </content>
                                    <br/>
                                    <content styleCode="bold"> (N=114)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> All Doses of Guanfacine Extended-Release Tablets (N=221)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Headache<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 11%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 16%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 17%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Insomnia<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Diarrhea<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Lethargy<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Constipation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dry Mouth<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Adverse reactions ≥2% for all doses of guanfacine extended-release tablets and &gt;rate in placebo in any dose group but did not meet this criteria in all doses combined: affect lability (affect lability, mood swings), increased weight, syncope/loss of consciousness (loss of consciousness, presyncope, syncope), dyspepsia, tachycardia (tachycardia, sinus tachycardia), and bradycardia (bradycardia, sinus bradycardia).<br/> a: The insomnia term includes insomnia, initial insomnia, middle insomnia, terminal insomnia, and sleep disorder.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID129" width="623" styleCode="Noautorules">
                           <caption/>
                           <col width="195"/>
                           <col width="201"/>
                           <col width="227"/>
                           <tbody>
                              <tr>
                                 <td colspan="3" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Table 9:  Percentage of Patients Experiencing Most Common (≥ 5% and at least twice the rate for placebo) Adverse Reactions in the Monotherapy Flexible Dose Study 5</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Adverse Reaction Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <content styleCode="bold"> (N=155)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> All Doses of Guanfacine Extended-Release Tablets (N=157)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Somnolence<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 23%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 54%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Insomnia<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hypotension<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 9%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dry Mouth<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Postural Dizziness<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Bradycardia<sup>d</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" valign="top" styleCode="Lrule Botrule Rrule" align="left"> a: The somnolence term includes somnolence, sedation, and hypersomnia.<br/> b: The insomnia term includes insomnia, initial insomnia, middle insomnia, terminal insomnia, and sleep disorder. c: The hypotension term includes hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased).<br/> d: The bradycardia term includes bradycardia and sinus bradycardia.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID56">There were no   specific adverse reactions ≥2% in any treatment group that led to   discontinuation in the monotherapy flexible dose study (Study 5).</paragraph>
                        <table ID="ID130" width="632" styleCode="Noautorules">
                           <caption/>
                           <col width="194"/>
                           <col width="185"/>
                           <col width="253"/>
                           <tbody>
                              <tr>
                                 <td colspan="3" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Table 10:  Other Common Adverse Reactions (≥2% for all doses of Guanfacine  Extended-Release Tablets and &gt;rate than in placebo) in the Monotherapy Flexible Dose Study 5</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Guanfacine Extended-Release Tablets</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Adverse Reaction Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <content styleCode="bold"> (N=155)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> All Doses of Guanfacine Extended-Release Tablets  (N=157)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Headache<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 27%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Fatigue<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 12%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 22%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dizziness<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 16%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Decreased Appetite<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 14%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 15%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Abdominal Pain<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 12%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Irritability<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Anxiety<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Rash<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Constipation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Increased Weight<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Abdominal/Stomach Discomfort<sup>d</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Pruritus<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Adverse reactions ≥2% for all doses of guanfacine extended-release tablets and &gt;rate in placebo in any dose group but did not meet this criteria in all doses combined: nausea, diarrhea, vomiting, and depression (depressed mood, depression, depressive symptom).<br/> a: The abdominal pain term includes abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.<br/> b: The anxiety term includes anxiety and nervousness.<br/> c: The rash term includes rash, rash generalized, and rash papular.<br/> d: The abdominal/stomach discomfort term includes abdominal discomfort, epigastric discomfort, and stomach discomfort.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID58">
                           <content styleCode="underline">Adjunctive   Trial</content>
                        </paragraph>
                        <table ID="ID131" width="635" styleCode="Noautorules">
                           <caption/>
                           <col width="157"/>
                           <col width="111"/>
                           <col width="111"/>
                           <col width="117"/>
                           <col width="137"/>
                           <tbody>
                              <tr>
                                 <td colspan="5" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Table 11:  Percentage of Patients Experiencing Most Common (≥5% and at least twice the rate for placebo) Adverse Reactions in the Short-Term Adjunctive Study 3</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="bottom" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Guanfacine Extended-Release Tablets + stimulant</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Adverse Reaction Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo+</content>
                                    <br/>
                                    <content styleCode="bold"> stimulant</content>
                                    <br/>
                                    <content styleCode="bold"> (N=153)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> AM </content>
                                    <br/>
                                    <content styleCode="bold"> (N=150)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> PM </content>
                                    <br/>
                                    <content styleCode="bold"> (N=152)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> All Doses (N=302)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Somnolence<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Insomnia<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 14%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 12%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Abdominal Painc<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 12%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Fatigue<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 12%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dizziness<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Decreased Appetite<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Nausea<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"> a: The somnolence term includes somnolence, sedation, and hypersomnia.<br/> b: The insomnia term includes insomnia, initial insomnia, middle insomnia, terminal insomnia, and sleep disorder.<br/> c: The abdominal pain term includes abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID60">There were no specific adverse reactions ≥2% in any   treatment group that led to discontinuation in the short-term adjunctive   study (Study 3).</paragraph>
                        <table ID="ID132" width="648" styleCode="Noautorules">
                           <caption/>
                           <col width="152"/>
                           <col width="99"/>
                           <col width="124"/>
                           <col width="118"/>
                           <col width="155"/>
                           <tbody>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Table 12:  Other Common Adverse Reactions (≥2% for all doses of Guanfacine Extended-Release Tablets and &gt;rate than in placebo) in the Short-Term Adjunctive Study 3</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="bottom" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Guanfacine Extended-Release Tablets + stimulant</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Adverse Reaction</content>
                                    <br/>
                                    <content styleCode="bold"> Term</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                    <content styleCode="bold"> (N=153)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> AM </content>
                                    <br/>
                                    <content styleCode="bold"> (N=150)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> PM </content>
                                    <br/>
                                    <content styleCode="bold"> (N=152)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> All Doses of Guanfacine Extended-Release Tablets</content>
                                    <br/>
                                    <content styleCode="bold"> (N=302)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Headache<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 21%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 21%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 21%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Diarrhea<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hypotension<sup>a</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Constipation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Affect Lability<sup>b</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Dry Mouth<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Bradycardia<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Postural Dizziness<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Rash<sup>d</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nightmare<sup>e</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Tachycardia<sup>f</sup>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Adverse reactions ≥2% for all doses of guanfacine extended-release tablets and &gt;rate in placebo in any dose group but did not meet this criteria in all doses combined: irritability, vomiting, asthma (asthma, bronchospasm, wheezing), and enuresis (enuresis, nocturia, urinary incontinence).<br/> a: The hypotension term includes hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased.<br/> b: The affect lability term includes affect lability and mood swings.<br/> c: The bradycardia term includes bradycardia and sinus bradycardia. <br/> d: The rash term includes rash, rash generalized, and rash papular.<br/> e: The nightmare term includes abnormal dreams, nightmare, and sleep terror.<br/> f: The tachycardia term includes tachycardia and sinus tachycardia.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID62">
                           <content styleCode="underline">Effects on   Blood Pressure and Heart Rate</content>
                        </paragraph>
                        <paragraph>In the monotherapy pediatric, short-term, controlled trials   (Studies 1 and 2), the maximum mean changes from baseline in seated systolic   blood pressure, diastolic blood pressure, and pulse were −5.4   mmHg,−3.4 mmHg, and −5.5 bpm, respectively, for all doses   combined (generally one week after reaching target doses). For the respective   fixed doses 1 mg/day, 2 mg/day, 3 mg/day or 4 mg/day the maximum mean changes   in seated systolic blood pressure were -4.3 mmHg, -5.5 mmHg, -5.4 mmHg and   -8.2 mmHg. For these  respective  fixed  doses  the  maximum  mean  changes    in  seated  diastolic  blood  pressure were -3.4 mmHg, -3.3 mmHg, -4.4 mmHg   and -5.4 mmHg. For these respective fixed doses the maximum mean changes in   seated pulse were -4.8 bpm, -3.1 bpm, -6.5 bpm and -8.6 bpm. Decreases in   blood pressure and heart rate were usually modest and asymptomatic; however,   hypotension and bradycardia can occur. Hypotension was reported as an adverse   reaction for 7% of the guanfacine extended-release tablets group and 3% of   the placebo group. This includes orthostatic hypotension, which was reported   for 1% of the guanfacine extended-release tablets group and none in the   placebo group. These findings were generally similar in the monotherapy   flexible dose trials (Studies 4 and 5). In the adjunctive trial, hypotension   (3%) and bradycardia (2%) were observed in patients treated with guanfacine   extended-release tablets as compared to none in the placebo group. In   long-term, open-label studies, (mean exposure of approximately 10 months),   maximum decreases in systolic and diastolic blood pressure occurred in the   first month of therapy. Decreases were less pronounced over time. Syncope   occurred in 1% of pediatric patients in the clinical program. The majority of   these cases occurred in the long-term, open-label studies.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Discontinuation   of Treatment</content>
                        </paragraph>
                        <paragraph>Blood pressure and pulse may increase above baseline values   following discontinuation of guanfacine extended-release tablet. In five   studies of children and adolescents <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID111">14</linkHtml>)],</content>   increases in mean systolic and diastolic blood pressure averaging   approximately 3 mmHg and increases in heart rate averaging 5 beats per minute   above original baseline were observed upon discontinuation with tapering of   guanfacine extended-release tablets<sup>+</sup>. In a maintenance of efficacy   study, increases in blood pressure and heart rate above baseline slowly   diminished over the follow up period, which ranged between 3 and 26 weeks   post final dose; the estimated average time to return to baseline was between   six and twelve months. In this study, the increases in blood pressure and   pulse were not considered serious or associated with adverse events. However,   individuals may have larger increases than reflected by the mean changes.</paragraph>
                        <paragraph>In postmarketing experience, following abrupt discontinuation of   guanfacine extended-release tablets rebound hypertension and hypertensive   encephalopathy have been reported <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID40">5.4</linkHtml>)   and Adverse Reactions (<linkHtml href="#ID64">6.2</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Effects on   Height, Weight, and Body Mass Index (BMI)</content>
                        </paragraph>
                        <paragraph>Patients taking guanfacine extended-release tablets demonstrated   similar growth compared to normative data. Patients taking guanfacine   extended-release tablets had a mean increase in weight of 0.5 kg compared to   those receiving placebo over a comparable treatment period. Patients   receiving guanfacine extended-release tablets for at least 12 months in   open-label studies gained an average of 8 kg in weight and 8 cm (3 in) in   height. The height, weight, and BMI percentile remained stable in patients at   12 months in the long-term studies compared to when they began receiving   guanfacine extended-release tablets.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Other   Adverse Reactions Observed in Clinical Studies</content>
                        </paragraph>
                        <paragraph>Table 13 includes additional adverse reactions observed in   short-term, placebo-controlled and long-term, open-label clinical studies not   included elsewhere in section <linkHtml href="#ID46">6.1</linkHtml>, listed by organ   system.</paragraph>
                        <table ID="ID133" width="474" styleCode="Noautorules">
                           <caption/>
                           <col width="174"/>
                           <col width="300"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Table 13: Other adverse reactions observed in clinical studies</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Body System</content>
                                    <br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Adverse Reaction</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="left"> Cardiac<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="left"> Atrioventricular block<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="left"> General<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="left"> Asthenia, chest pain<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="left"> Immune System Disorders<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="left"> Hypersensitivity<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="left"> Investigations<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="left"> Increased alanine amino transferase<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="left"> Nervous system<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="left"> Convulsion<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="left"> Renal<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="left"> Increased urinary frequency<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Lrule Botrule Rrule" align="left"> Vascular<br/>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Rrule" align="left"> Hypertension, pallor<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID64">
                     <id root="54ed281f-7f96-4f4f-bd9e-21a87015a69d"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID65">The following adverse reactions have been identified during   post-approval use of guanfacine. Because these reactions are reported   voluntarily from a population of uncertain size, it is not always possible to   reliably estimate their frequency or establish a causal relationship to drug   exposure.</paragraph>
                        <paragraph>Less frequent, possibly guanfacine-related events observed in the   post-marketing study and/or reported spontaneously, not included in section <linkHtml href="#ID46">6.1</linkHtml>,   include:</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">General:</content>
                           </content> edema, malaise, tremor </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiovascular</content>
                           </content>: palpitations,   tachycardia, rebound hypertension, hypertensive encephalopathy</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Central Nervous System</content>
                           </content>:   paresthesias, vertigo</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Eye Disorders: </content>
                           </content>blurred vision</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Musculo-Skeletal System</content>
                           </content>:   arthralgia, leg cramps, leg pain, myalgia</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Psychiatric</content>
                           </content>: confusion,   hallucinations</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Reproductive System, Male</content>
                           </content>:   erectile dysfunction </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Respiratory System</content>
                           </content>: dyspnea</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Skin and Appendages</content>
                           </content>: alopecia,   dermatitis, exfoliative dermatitis, pruritus, rash</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Special Senses:</content>
                           </content> alterations in   taste</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID68">
               <id root="b84ad365-f941-4d23-8176-ca42a1f6fe48"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="ID69">Table 14 contains clinically important drug interactions with   guanfacine extended-release tablets <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID100">12.3</linkHtml>)].</content>
                  </paragraph>
                  <table ID="ID134" width="100%" styleCode="Noautorules">
                     <caption>  Table 14: Clinically Important Drug Interaction: Effect of other Drugs on Guanfacine Extended-Release Tablets </caption>
                     <col width="33%"/>
                     <col width="33%"/>
                     <col width="32%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Toprule Botrule Rrule" align="left"> Concomitant Drug Name or<br/> Drug Class<br/>
                           </td>
                           <td styleCode=" Toprule Botrule Rrule" align="left"> Clinical Rationale and <br/> Magnitude of Drug Interaction<br/>
                           </td>
                           <td styleCode=" Toprule Botrule Rrule" align="left"> Clinical Recommendation<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> Strong and moderate CYP3A4 inhibitors, e.g., ketoconazole, fluconazole<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in an increase in exposure<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Consider dose reduction [see Dosage and administration (<linkHtml href="#ID20">2.7</linkHtml>)]<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Consider dose increase [see Dosage and administration (<linkHtml href="#ID20">2.7</linkHtml>)]<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20230911"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID72" styleCode="Disc">
                           <item>Strong and moderate   CYP3A4 inhibitors   increase guanfacine exposure.   Decrease guanfacine   extended-release tablets to 50% of target dosage when coadministered with strong and moderate CYP3A4 inhibitors (<linkHtml href="#ID20">2.7</linkHtml>).</item>
                           <item>Strong   and moderate CYP3A4   inducers decrease guanfacine   exposure. Based on patient response,   consider titrating guanfacine extended-release tablets dosage up to double the target   dosage over 1 to 2   weeks (<linkHtml href="#ID20">2.7</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID73">
               <id root="4d6c6521-52db-4bab-8746-8bff6eafadc4"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240223"/>
               <component>
                  <section ID="ID74">
                     <id root="fa6810bd-875b-4a87-b437-a7c7303349cb"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID75">
                           <content styleCode="underline">Risk   Summary</content>
                        </paragraph>
                        <paragraph>Available data with guanfacine over decades of use in pregnant   women have not identified a drug- associated risk of major birth defects,   miscarriage or adverse maternal or fetal outcomes. However, use of guanfacine   in pregnant women over this time has been infrequent. In animal reproduction   studies, rabbits and rats exposed to 3 and 4 times the maximum recommended   human dose (MRHD), respectively, showed no adverse outcomes. However, higher   doses were associated with reduced fetal survival and maternal toxicity (see   Data).</paragraph>
                        <paragraph>The estimated background risk of major birth defects and   miscarriage for the indicated population is unknown. All pregnancies have a   background risk of birth defect, loss, or other adverse outcomes. In the U.S.   general population, the estimated risk of major birth defects and miscarriage   in clinically recognized pregnancies is 2% to 4% and 15% to 20%,   respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Reproduction studies conducted in rats have shown that guanfacine   crosses the placenta. However, administration of guanfacine to rabbits and   rats during organogenesis at 3 (rabbit) and 4 (rat) times the MRHD of 0.12   mg/kg/day on a mg/m2 basis resulted in no evidence of harm to the fetus.   Higher doses (13.5 times the MRHD in both rabbits and rats) were associated   with reduced fetal survival and maternal toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20240223"/>
                  </section>
               </component>
               <component>
                  <section ID="ID76">
                     <id root="c1edcd00-6a46-4940-91c0-dcad45e031ab"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID77">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of guanfacine in human milk or   the effects on the breastfed infant. The effects on milk production are also   unknown. Guanfacine is present in the milk of lactating rats (<content styleCode="italics">see Data</content>).   If a drug is present in animal milk, it is likely that the drug will be   present in human milk. If an infant is exposed to guanfacine through   breastmilk, monitor for symptoms of hypotension and bradycardia such as   sedation, lethargy and poor feeding (<content styleCode="italics">see Clinical Considerations</content>). The   developmental and health benefits of breastfeeding should be considered along   with the mother's clinical need for guanfacine extended-release tablets   and any potential adverse effects on the breastfed child from guanfacine   extended-release tablets or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Monitor breastfeeding infants exposed to guanfacine through   breastmilk for sedation, lethargy, and poor feeding.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>Guanfacine was excreted in breast milk of lactating rats at a   concentration comparable to that observed in blood, but slightly less than   the concentration in plasma when administered following a single oral dose of   5 mg/kg. The concentration of drug in animal milk does not necessarily   predict the concentration of drug in human milk.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID78">
                     <id root="d4e6e234-23ca-4a6b-9c34-1321a763b8bd"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID79">Safety and efficacy of guanfacine extended-release tablets in   pediatric patients less than 6 years of age have not been established. The   efficacy of guanfacine extended-release tablets was studied for the treatment   of ADHD in five controlled monotherapy clinical trials (up to 15 weeks in   duration), one randomized withdrawal study and one controlled adjunctive   trial with psychostimulants (8 weeks in duration) in children and adolescents   ages 6-17 who met DSM-IV<sup>®</sup> criteria for ADHD <content styleCode="italics">[see Adverse   Reactions (<linkHtml href="#ID44">6</linkHtml>) and Clinical Studies (<linkHtml href="#ID111">14</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In studies in juvenile rats, guanfacine alone produced a slight   delay in sexual maturation in males and females at 2 to 3 times the maximum   recommended human dose (MRHD). Guanfacine in combination with methylphenidate   produced a slight delay in sexual maturation and decreased growth as measured   by a decrease in bone length in males at a dose of guanfacine comparable to   the MRHD and a dose of methylphenidate approximately 4 times the MRHD.</paragraph>
                        <paragraph>In a study where juvenile rats were treated with guanfacine alone   from 7 to 59 days of age, development was delayed as indicated by a slight   delay in sexual maturation and decreased body weight gain in males at 2   mg/kg/day and in females at 3 mg/kg/day. The No Adverse Effect Level (NOAEL)   for delayed sexual maturation was 1 mg/kg/day, which is equivalent to the   MRHD of 4 mg/day, on a mg/m<sup>2</sup> basis. The effects on fertility were   not evaluated in this study.</paragraph>
                        <paragraph>In a study where juvenile rats were treated with guanfacine in   combination with methylphenidate from 7 to 59 days of age, a decrease in ulna   bone length and a slight delay in sexual maturation were observed in males   given 1 mg/kg/day of guanfacine in combination with 50 mg/kg/day of   methylphenidate. The NOAELs for these findings were 0.3 mg/kg of guanfacine   in combination with 16 mg/kg/day of methylphenidate, which are equivalent to   0.3 and 1.4 times the MRHD of 4 mg/day and 54 mg/day for guanfacine and   methylphenidate, respectively, on a mg/m<sup>2</sup> basis. These findings   were not observed with guanfacine alone at 1 mg/kg/day or methylphenidate   alone at 50 mg/kg/day.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID80">
                     <id root="a06f95a1-80f7-4e37-b576-21c4cb34dd04"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID81">The safety and efficacy of guanfacine extended-release tablets in   geriatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID82">
                     <id root="4ff3d157-1e80-490a-8032-b347ee964d01"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID83">It may be necessary to reduce the dosage in patients with   significant impairment of renal function <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID100">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID84">
                     <id root="e7a4c25d-05cb-4c4b-b6c4-5873c4dc36f1"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID85">It may be   necessary to reduce the dosage in patients with significant impairment of   hepatic function <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID100">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID86">
               <id root="8f9ec34e-d441-4949-adb0-9592f75c9d98"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20230911"/>
               <component>
                  <section ID="ID87">
                     <id root="ffeeb53e-bd75-4a2a-b335-80c896462c74"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph ID="ID88">Guanfacine extended-release tablet is not a controlled substance   and has no known potential for abuse or dependence.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID89">
               <id root="ae98a18e-b059-4bc8-ae8c-eb5e45554e4f"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID90">
                     <content styleCode="underline">Symptoms</content>
                  </paragraph>
                  <paragraph>Postmarketing reports of guanfacine overdosage indicate that   hypotension, drowsiness, lethargy, and bradycardia have been observed   following overdose. Initial hypertension may develop early and may be   followed by hypotension. Similar symptoms have been described in voluntary   reports to the American Association of Poison Control Center's National   Poison Data System. Miosis of the pupils may be noted on examination. No   fatal overdoses of guanfacine have been reported in published literature.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Treatment</content>
                  </paragraph>
                  <paragraph>Consult a Certified Poison Control Center by calling   1-800-222-1222 for up-to-date guidance and advice.</paragraph>
                  <paragraph>Management of guanfacine extended-release tablets overdose should   include monitoring for and the treatment of initial hypertension, if that   occurs, as well as hypotension, bradycardia, lethargy and respiratory   depression. Children and adolescents who develop lethargy should be observed   for the development of more serious toxicity including coma, bradycardia and   hypotension for up to 24 hours, due to the possibility of delayed onset   hypotension.</paragraph>
               </text>
               <effectiveTime value="20230911"/>
            </section>
         </component>
         <component>
            <section ID="ID91">
               <id root="24ed01ab-da8a-47a9-a6a6-0e642ce16648"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID92">Guanfacine extended-release tablets, USP are a once-daily,   extended-release formulation of guanfacine hydrochloride (HCl) in a matrix   tablet formulation for oral administration only. The chemical designation is   N-amidino-2-(2,6-dichlorophenyl) acetamide monohydrochloride. The molecular   formula is C<sub>9</sub>H<sub>9</sub>Cl<sub>2</sub> N<sub>3</sub>O·HCl   corresponding to a molecular weight of 282.55. The chemical structure is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID94">Guanfacine HCl, USP is a white or almost off-white crystalline   powder, soluble in methanol. Each tablet contains guanfacine HCl equivalent   to 1 mg, 2 mg, 3 mg, or 4 mg of guanfacine base. The tablets also contains   fumaric acid, glyceryl dibehenate, hypromellose, lactose monohydrate, methacrylic acid-ethyl acrylate copolymer, microcrystalline   cellulose, polysorbate 80 and sodium lauryl sulfate.   In addition, the 3-mg and 4-mg tablets also contain D &amp; C yellow #10   aluminium lake and FD &amp; C blue #1 aluminium lake.</paragraph>
                  <paragraph>"FDA   approved dissolution test specifications differ from USP".</paragraph>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Figure 01</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bc9cc5d2-e098-41da-ae90-0944715d6b92-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID95">
               <id root="2d25a467-a95b-48de-a173-bade2659646c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241125"/>
               <component>
                  <section ID="ID96">
                     <id root="b06cec08-f247-46ad-bda3-a237d39265e7"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID97">Guanfacine is a central alpha<sub>2A</sub>-adrenergic receptor   agonist. Guanfacine is not a central nervous system (CNS) stimulant. The   mechanism of action of guanfacine in ADHD is not known.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID98">
                     <id root="62beb1d1-7d61-4e26-8678-dcaa842b5b57"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID99">Guanfacine is a selective central alpha<sub>2A</sub>-adrenergic   receptor agonist in that it has a 15-20 times higher affinity for this   receptor subtype than for the alpha<sub>2B</sub> or alpha<sub>2C</sub>   subtypes.</paragraph>
                        <paragraph>Guanfacine is a known antihypertensive agent. By stimulating   central alpha<sub>2A</sub>-adrenergic receptors, guanfacine reduces   sympathetic nerve impulses from the vasomotor center to the heart and blood   vessels. This results in a decrease in peripheral vascular resistance and a   reduction in heart rate.</paragraph>
                        <paragraph>In a thorough QT study, the administration of two dose levels of   immediate-release guanfacine (4 mg and 8 mg) produced concentrations   approximately 2 to 4 times the concentrations observed with the maximum   recommended dose of guanfacine extended-release tablets of 0.12 mg/kg.   Guanfacine was not shown to prolong the QTc interval to any clinically   relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
               <component>
                  <section ID="ID100">
                     <id root="126a9d9c-d9bc-45b2-ae65-a4e3b9912e4b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID101">
                           <content styleCode="underline">Absorption   and Distribution</content>
                        </paragraph>
                        <paragraph>Guanfacine is readily absorbed and approximately 70% bound to   plasma proteins independent of drug concentration. After oral administration   of guanfacine extended-release tablets the time to peak plasma concentration   is approximately 5 hours in children and adolescents with ADHD.</paragraph>
                        <paragraph>Immediate-release guanfacine and extended-release guanfacine have   different pharmacokinetic characteristics; dose substitution on a milligram   per milligram basis will result in differences in exposure.</paragraph>
                        <paragraph>A comparison across studies suggests that the C<sub>max</sub> is   60% lower and AUC<sub>0-∞</sub> 43% lower, respectively, for   extended-release guanfacine compared to immediate-release guanfacine.   Therefore, the relative bioavailability of extended-release guanfacine to   immediate-release guanfacine is 58%. The mean pharmacokinetic parameters in   adults following the administration of guanfacine extended-release tablets 1   mg once daily and immediate-release guanfacine 1 mg once daily are summarized   in <linkHtml href="#ID135">Table 15</linkHtml>.</paragraph>
                        <table ID="ID135" width="544" styleCode="Noautorules">
                           <caption/>
                           <col width="118"/>
                           <col width="222"/>
                           <col width="204"/>
                           <tbody>
                              <tr>
                                 <td colspan="3" valign="bottom" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Table 15: Comparison  of Pharmacokinetics: Guanfacine Extended-Release vs.  Immediate Release Guanfacine in Adults</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center">
                                    <br/>
                                    <content styleCode="bold"> Parameter</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Guanfacine extended-release </content>
                                    <br/>
                                    <content styleCode="bold"> 1 mg once daily </content>
                                    <br/>
                                    <content styleCode="bold"> (n=52)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Immediate-release guanfacine </content>
                                    <br/>
                                    <content styleCode="bold"> 1 mg once daily</content>
                                    <br/>
                                    <content styleCode="bold">  (n=12)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> C<sub>max </sub>(ng/mL)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.0 ± 0.3<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.5 ± 0.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> AUC<sub>0-∞</sub> (ng·h/mL)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 32 ± 9<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 56 ± 15<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> t<sub>max</sub> (h)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6.0 (4.0 – 8.0)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3.0 (1.5-4.0)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> t<sub>½ </sub>(h)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 18 ± 4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 16 ± 3<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID103">Note: Values are mean +/- SD, except for   t<sub>max</sub> which is median (range)</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1: Comparison of Pharmacokinetics Guanfacine   Extended-Release vs. Immediate-Release Guanfacine in Adults</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                        <paragraph ID="ID105">Exposure to guanfacine was higher in children (ages 6-12) compared   to adolescents (ages 13-17) and adults. After oral administration of multiple   doses of guanfacine extended-release tablets 4 mg, the C<sub>max</sub> was 10   ng/mL compared to 7 ng/mL and the AUC was 162 ng·h/mL compared to 116 ng·h/mL   in children (ages 6-12) and adolescents (ages 13-17), respectively. These   differences are probably attributable to the lower body weight of children   compared to adolescents and adults.</paragraph>
                        <paragraph>The pharmacokinetics were affected by intake of food when a single   dose of guanfacine extended-release tablets 4 mg was administered with a   high-fat breakfast. The mean exposure increased (C<sub>max</sub> ~75% and AUC   ~40%) compared to dosing in a fasted state.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dose Proportionality</content>
                        </paragraph>
                        <paragraph>Following administration of guanfacine extended-release tablets in   single doses of 1 mg, 2 mg, 3 mg, and 4 mg to adults, C<sub>max</sub> and AUC<sub>0-∞</sub>   of guanfacine were proportional to dose. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism and Elimination</content>.</paragraph>
                        <paragraph>In vitro studies with human liver microsomes and recombinant CYP's   demonstrated that guanfacine was primarily metabolized by CYP3A4. In pooled   human hepatic microsomes, guanfacine did not inhibit the activities of the   major cytochrome P450 isoenzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19,   CYP2D6 or CYP3A4/5); guanfacine is also not an inducer of CYP3A, CYP1A2 and   CYP2B6. Guanfacine is a substrate of CYP3A4/5 and exposure is affected by   CYP3A4/5 inducers/inhibitors.</paragraph>
                        <paragraph>Guanfacine inhibits MATE1 and OCT1, but does not inhibit BSEP,   MRP2, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, or MATE2K. Guanfacine is a   substrate of OCT1 and OCT2, but not BCRP, OATP1B1, OATP1B3, OAT1, OAT3,   MATE1, or MATE2. Concomitant administration of guanfacine with OCT1   substrates might potentially increase the exposure of these OCT1 substrates.</paragraph>
                        <paragraph ID="ID149">
                           <content styleCode="bold">
                              <content styleCode="underline">Studies   in Specific Populations</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Renal   Impairment</content>
                        </paragraph>
                        <paragraph>The impact of renal impairment on the pharmacokinetics of   guanfacine in children was not assessed. In adult patients with impaired   renal function, the cumulative urinary excretion of guanfacine and the renal   clearance diminished as renal function decreased. In patients on   hemodialysis, the dialysis clearance was about 15% of the total clearance.   The low dialysis clearance suggests that the hepatic elimination (metabolism)   increases as renal function decreases.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hepatic   Impairment</content>
                        </paragraph>
                        <paragraph>The impact of hepatic impairment on PK of guanfacine in children   was not assessed. Guanfacine in adults is cleared both by the liver and the   kidney, and approximately 50% of the clearance of guanfacine is hepatic <content styleCode="italics">[see   Hepatic Impairment (<linkHtml href="#ID84">8.7</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug   Interaction Studies</content>
                        </paragraph>
                        <paragraph>Guanfacine is primarily metabolized by CYP3A4 and its plasma   concentrations can be affected significantly by CYP3A4 inhibitors or inducers   (<linkHtml href="#ID104">Figure 2</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 2: Effect of Other Drugs on the Pharmacokinetics (PK) of   Guanfacine Extended-Release Tablets</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM3"/>
                        <paragraph ID="ID151">Guanfacine does not significantly affect exposures of methylphenidate and lisdexamfetamine when coadministered (<linkHtml href="#ID152">Figure 3</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 3: Effect of Guanfacine Extended-Release Tablets on the Pharmacokinetics (PK) of Other Drugs</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM4"/>
                     </text>
                     <effectiveTime value="20241125"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bc9cc5d2-e098-41da-ae90-0944715d6b92-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Figure 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bc9cc5d2-e098-41da-ae90-0944715d6b92-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Figure 3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bc9cc5d2-e098-41da-ae90-0944715d6b92-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID108">
               <id root="46aecec6-4e9f-4a79-9743-6f0756c9157d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230911"/>
               <component>
                  <section ID="ID109">
                     <id root="820af377-b2ca-4ba0-a9d2-89539151efb6"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID110">
                           <content styleCode="italics">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>No carcinogenic effect of guanfacine was observed in studies of 78   weeks in mice or 102 weeks in rats at doses up to 6.8 times the maximum   recommended human dose of 0.12 mg/kg/day on a mg/m<sup>2</sup> basis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Guanfacine was not genotoxic in a variety of test models,   including the Ames test and an in vitro chromosomal aberration test; however,   a marginal increase in numerical aberrations (polyploidy) was observed in the   latter study.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>No adverse effects were observed in fertility studies in male and   female rats at doses up to 22 times the maximum recommended human dose on a   mg/m<sup>2</sup> basis.</paragraph>
                     </text>
                     <effectiveTime value="20230911"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID111">
               <id root="7f23d728-206b-4da2-ada6-eef94ea4eb20"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID112">Efficacy of guanfacine extended-release tablets in the treatment   of ADHD was established in children and adolescents (6 to 17 years) in:</paragraph>
                  <paragraph>•    Five short-term, placebo-controlled monotherapy trials   (Studies 1, 2, 4, 5, and 6).</paragraph>
                  <paragraph>•    One short-term, placebo-controlled adjunctive trial with   psychostimulants (Study 3).</paragraph>
                  <paragraph>•    One long-term, placebo-controlled monotherapy maintenance   trial (Study 7). </paragraph>
                  <paragraph>
                     <content styleCode="underline">Studies 1   and 2: Fixed-dose Guanfacine Extended-Release Tablets Monotherapy</content>
                  </paragraph>
                  <paragraph>Study 1 (301 study) was a double-blind, placebo-controlled,   parallel-group, fixed-dose study, in which efficacy of once daily dosing with   guanfacine extended-release tablets (2 mg, 3 mg and 4 mg) was evaluated for 5   weeks (n=345) in children and adolescents aged 6-17 years. Study 2 (304   study) was a double-blind, placebo-controlled, parallel-group, fixed-dose   study, in which efficacy of once daily dosing with guanfacine   extended-release tablets (1 mg, 2 mg, 3 mg and 4 mg) was evaluated for 6   weeks (n=324) in children and adolescents aged 6-17 years. In both studies,   randomized patients in 2 mg, 3 mg and 4 mg dose groups were titrated to their   target fixed dose, and  continued on the same dose until a dose tapering   phase started. The lowest dose of 1 mg used in Study 2 was not randomized to   patients weighing more than 50 kg. Patients who weighed less than 25 kg were   not included in either study.</paragraph>
                  <paragraph>Signs and symptoms of ADHD were evaluated on a once weekly basis   using the clinician administered and scored ADHD Rating Scale (ADHD-RS-IV),   which includes both hyperactive/impulsive and inattentive subscales. The   primary efficacy outcome was the change from baseline to endpoint in   ADHD-RS-IV total scores. Endpoint was defined as the last post-randomization   treatment week for which a valid score was obtained prior to dose tapering   (up to Week 5 in Study 1 and up to Week 6 in Study 2).</paragraph>
                  <paragraph>The mean reductions in ADHD-RS-IV total scores at endpoint were   statistically significantly greater for guanfacine extended-release tablets   compared to placebo for Studies 1 and 2. Placebo-adjusted changes from   baseline were statistically significant for each of the 2 mg, 3 mg, and 4 mg   guanfacine extended-release tablets randomized treatment groups in both   studies, as well as the 1 mg guanfacine extended-release tablets treatment group   that was included only in Study 2 (see <linkHtml href="#ID136">Table 16</linkHtml>).</paragraph>
                  <paragraph>Dose-responsive efficacy was evident, particularly when data were   examined on a weight-adjusted (mg/kg) basis. When evaluated over the dose   range of 0.01-0.17 mg/kg/day, clinically relevant improvements were observed   beginning at doses in the range 0.05-0.08 mg/kg/day. Doses up to 0.12   mg/kg/day were shown to provide additional benefit.</paragraph>
                  <paragraph>In the monotherapy trials (Studies 1 and 2), subgroup analyses   were performed to identify any differences in response based on gender or age   (6-12 vs. 13-17). Analyses of the primary outcome did not suggest any   differential responsiveness on the basis of gender. Analyses by age revealed   a statistically significant treatment effect only in the 6-12 age subgroup.   Due to the relatively small proportion of adolescent patients (ages 13-17)   enrolled into these studies (approximately 25%), these data may not have been   sufficient to demonstrate efficacy in the adolescent patients. In these   studies, patients were randomized to a fixed dose of guanfacine   extended-release tablets rather than optimized by body weight. Therefore,   some adolescent patients were randomized to a dose that might have resulted   in relatively lower plasma guanfacine concentrations compared to the younger   patients. Over half (55%) of the adolescent patients received doses of   0.01-0.04 mg/kg. In studies in which systematic pharmacokinetic data were   obtained, there was a strong inverse correlation between body weight and   plasma guanfacine concentrations.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 16:   Fixed dose Studies</content>
                  </paragraph>
                  <table ID="ID136" width="624" styleCode="Noautorules">
                     <caption>  Table 16: Fixed dose Studies </caption>
                     <col width="93"/>
                     <col width="131"/>
                     <col width="116"/>
                     <col width="139"/>
                     <col width="144"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode=" Toprule" align="left">
                              <content styleCode="bold"> Study </content>
                              <br/>
                              <content styleCode="bold"> Number</content>
                              <br/>
                           </td>
                           <td styleCode=" Toprule" align="left">
                              <content styleCode="bold"> Treatment Group</content>
                              <br/>
                           </td>
                           <td colspan="3" styleCode=" Toprule Botrule" align="center">
                              <content styleCode="bold"> Primary Efficacy Measure: ADHD-RS-IV Total Score</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule" align="left">
                              <content styleCode="bold"> (Age Range)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center">
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center">
                              <content styleCode="bold"> Mean Baseline</content>
                              <br/>
                              <content styleCode="bold"> Score (SD)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule" align="center">
                              <content styleCode="bold"> LS Mean Change </content>
                              <br/>
                              <content styleCode="bold"> from Baseline (SE)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule" align="center">
                              <content styleCode="bold"> Placebo-subtracted</content>
                              <br/>
                              <content styleCode="bold"> Difference<sup>a</sup> (95% CI)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule" align="left"> Study 1 <br/> (6 -17 years)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="left"> Guanfacine extended-release tablets 2 mg* Guanfacine extended-release tablets 3 mg* Guanfacine extended-release tablets 4 mg* Placebo<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> 36.1 (9.99)<br/> 36.8 (8.72)<br/> 38.4 (9.21)<br/> 38.1 (9.34)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -15.9 (1.37)<br/> -16.0 (1.38)<br/> -18.5 (1.39)<br/> -8.5 (1.42)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -7.4 (-11.3, -3.5)<br/> -7.5 (-11.4, -3.6)<br/> -10.0 (-13.9, -6.1)<br/> - <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule" align="left"> Study 2 <br/> (6 - 17 years)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="left"> Guanfacine extended-release tablets 1 mg*^ Guanfacine extended-release tablets 2 mg* Guanfacine extended-release tablets 3 mg* Guanfacine extended-release tablets 4 mg* Placebo<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> 41.7 (7.81)<br/> 39.9 (8.74)<br/> 39.1 (9.22)<br/> 40.6 (8.57)<br/> 39.3 (8.85)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -19.4 (1.69)<br/> -18.1 (1.60)<br/> -20.0 (1.64)<br/> -20.6 (1.60)<br/> -12.7 (1.60)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -6.8 (-11.3, -2.2)<br/> -5.4 (-9.9, -0.9)<br/> -7.3 (-11.8, -2.8)<br/> -7.9 (-12.3, -3.4)<br/> - <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID114">SD: standard deviation; SE: standard error; LS Mean:   least-squares mean; CI: unadjusted confidence interval.</paragraph>
                  <paragraph>a Difference (drug minus placebo) in least-squares   mean change from baseline.</paragraph>
                  <paragraph>* Doses statistically significantly superior to   placebo.</paragraph>
                  <paragraph>^ The lowest dose of 1 mg used in Study 2 was not   randomized to patients weighing more than 50 kg.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Study 3:   Flexible-dose Guanfacine Extended-Release Tablets as Adjunctive Therapy to   Psychostimulants</content>
                  </paragraph>
                  <paragraph>Study 3 (313 study) was a double-blind, randomized, placebo-controlled,   dose-optimization study, in which efficacy of once daily optimized dosing   (morning or evening) with guanfacine extended-release tablets (1 mg, 2 mg, 3   mg and 4 mg), when co-administered with psychostimulants, was evaluated for 8   weeks, in children and adolescents aged 6-17 years with a diagnosis of ADHD,   with a sub-optimal response to stimulants (n=455). Patients were started at   the 1 mg guanfacine extended-release tablets dose level and were titrated   weekly over a 5-week dose-optimization period to an optimal guanfacine   extended-release tablets dose not to exceed 4 mg/day based on tolerability   and clinical response. The dose was then maintained for a 3-week dose   maintenance period before entry to 1 week of dose tapering. Patients took   guanfacine extended-release tablets either in the morning or the evening   while maintaining their current dose of psychostimulant treatment given each   morning. Allowable psychostimulants in the study were ADDERALL XR<sup>®</sup>,   VYVANSE<sup>®</sup>, CONCERTA<sup>®</sup>, FOCALIN XR<sup>®</sup>, RITALIN   LA<sup>®</sup>, METADATE CD<sup>®</sup> or FDA-approved generic   equivalents.</paragraph>
                  <paragraph>Symptoms of ADHD were evaluated on a weekly basis by clinicians   using the ADHD Rating Scale (ADHD-RS-IV), which includes both   hyperactive/impulsive and inattentive subscales. The primary efficacy outcome   was the change from baseline to endpoint in ADHD-RS-IV total scores. Endpoint   was defined as the last post-randomization treatment week prior to dose   tapering for which a valid score was obtained (up to Week 8).</paragraph>
                  <paragraph>Mean reductions in ADHD-RS-IV total scores at endpoint were   statistically significantly greater for guanfacine extended-release tablets   given in combination with a psychostimulant compared to placebo given with a   psychostimulant for Study 3, for both morning and evening guanfacine   extended-release tablets dosing (see <linkHtml href="#ID137">Table 17</linkHtml>).   Nearly two-thirds (64.2%) of patients reached optimal doses in the 0.05-0.12   mg/kg/day range.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Studies 4,   5 and 6: Flexible-dose Guanfacine Extended-Release Tablets Monotherapy</content>
                  </paragraph>
                  <paragraph>Study 4 (314 study) was a double-blind, randomized,   placebo-controlled, dose-optimization study, in which efficacy of once daily   dosing (morning or evening) with guanfacine  extended-release tablets (1 mg,   2 mg, 3 mg, and 4 mg) was evaluated for 8 weeks in children aged 6-12 years   (n=340).</paragraph>
                  <paragraph>Signs and symptoms of ADHD were evaluated on a once weekly basis   using the clinician administered and scored ADHD Rating Scale (ADHD-RS-IV),   which includes both hyperactive/impulsive and inattentive subscales. The   primary efficacy outcome  was  the  change  from baseline score at endpoint   on the ADHD-RS-IV total scores. Endpoint was defined as the last   post-randomization treatment week for which a valid score was obtained prior   to dose tapering (up to Week 8).</paragraph>
                  <paragraph>Mean reductions in ADHD-RS-IV total scores at endpoint were   statistically significantly greater for guanfacine extended-release tablets   compared to placebo in both AM and PM dosing groups of guanfacine   extended-release tablets (see <linkHtml href="#ID148">Table 17</linkHtml>).</paragraph>
                  <paragraph>Study 5 (312 study) was a 15-week, double-blind, randomized,   placebo-controlled, dose-optimization study conducted in adolescents aged   13-17 years (n=314) to evaluate the efficacy and safety of guanfacine   extended-release tablets (1-7 mg/day; optimized dose range of 0.05-0.12   mg/kg/day) in the treatment of ADHD as measured by the ADHD Rating Scale-IV   (ADHD-RS-IV). Patients receiving guanfacine extended-release tablets showed   statistically significantly greater improvement on the ADHD-RS-IV total score   compared with patients receiving placebo (see <linkHtml href="#ID148">Table 17</linkHtml>).</paragraph>
                  <paragraph>Study 6 (316 study) was a 12-week (for children aged 6-12) or   15-week (for adolescents aged 13-17), randomized, double-blind,   parallel-group, placebo- and active-reference, dose-optimization study   conducted in pediatric patients (children and adolescents aged 6-17 years old   inclusive) (n=337) to assess the efficacy and safety of once-daily dosing   (children: 1-4 mg/day, adolescents: 1-7 mg/day; optimized dose range of 0.05   to 0.12 mg/kg/day) in the treatment of ADHD. Guanfacine extended-release tablets   were statistically superior to placebo on symptoms of ADHD in patients 6-17   years as measured by change from baseline in ADHD-RS-IV total scores (see <linkHtml href="#ID148">Table   17</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 17: Flexible-Dose studies</content>
                  </paragraph>
                  <table ID="ID137" width="624" styleCode="Noautorules">
                     <caption>  Flexible-Dose studies </caption>
                     <col width="77"/>
                     <col width="180"/>
                     <col width="120"/>
                     <col width="112"/>
                     <col width="135"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode=" Toprule Botrule" align="left">
                              <br/>
                           </td>
                           <td styleCode=" Toprule Botrule" align="center">
                              <br/>
                           </td>
                           <td colspan="3" styleCode=" Toprule Botrule" align="center">
                              <content styleCode="bold"> Primary Efficacy Measure: ADHD-RS-IV Total Score</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule" align="left">
                              <content styleCode="bold"> Study Number</content>
                              <br/>
                              <content styleCode="bold"> (Age Range)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="left">
                              <br/>
                              <content styleCode="bold"> Treatment Group</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="left">
                              <br/>
                              <content styleCode="bold"> Mean Baseline</content>
                              <br/>
                              <content styleCode="bold"> Score (SD)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="left">
                              <br/>
                              <content styleCode="bold"> LS Mean Change from Baseline (SE)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="left">
                              <br/>
                              <content styleCode="bold"> Placebo- subtracted Difference<sup>b</sup>
                              </content>
                              <br/>
                              <content styleCode="bold"> (95% CI)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule" align="center"> Study 3<sup>a</sup>
                              <br/> (6-17 years)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="left"> Guanfacine extended-release tablets 1-4 mg AM* Guanfacine extended-release tablets 1-4 mg PM* Placebo<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> 37.6 (8.13)<br/> 37.0 (7.65)<br/> 37.7 (7.75)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -20.3 (0.97)<br/> -21.2 (0.97)<br/> -15.9 (0.96)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -4.5 (-7.5, -1.4)<br/> -5.3 (-8.3, -2.3)<br/> - <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule" align="center"> Study 4 <br/> (6-12 years)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="left"> Guanfacine extended-release tablets 1-4 mg AM* Guanfacine extended-release tablets 1-4 mg PM* Placebo<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> 41.7 (6.39)<br/> 41.6 (6.66)<br/> 42.9 (6.29)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -20.0 (1.23)<br/> -20.4 (1.19)<br/> -10.6 (1.20)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -9.4 (-12.8, -6.0)<br/> -9.8 (-13.1, -6.4)<br/> - <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule" align="center"> Study 5 <br/> (13-17 years)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="left"> Guanfacine extended-release tablets 1-7 mg* Placebo<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> 39.9 (5.57)<br/> 40.0 (6.11)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -24.6 (1.06)<br/> -18.5 (1.08)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -6.03 (-8.87, -3.19)<br/> - <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule" align="center"> Study 6 <br/> (6-17 years)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="left"> Guanfacine extended-release tablets  1-7 mg* Placebo<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> 43.1 (5.47)<br/> 43.2 (5.60)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -23.89 (1.15)<br/> -15.01 (1.16)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule" align="center"> -8.88 (-11.94,  5.81)<br/> - <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID116">SD: standard deviation; SE: standard error; LS Mean:   least-squares mean; CI: unadjusted confidence interval.</paragraph>
                  <paragraph>a Treatment was given in combination with a   psychostimulant.</paragraph>
                  <paragraph>b Difference (drug minus placebo) in least-squares   mean change from baseline.</paragraph>
                  <paragraph>* Doses statistically significantly superior to   placebo.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Study 7: Long-Term Maintenance of Guanfacine Extended-Release   Tablets Efficacy</content>
                  </paragraph>
                  <paragraph>Study 7 (315 study) was a double-blind, placebo-controlled,   randomized withdrawal trial in pediatric patients aged 6 to 17 years with   DSM-IV-TR diagnosis of ADHD. The study consisted of an open-label phase,   including a 7-week dose optimization period to titrate patients to an optimal   dose (maximum 4 mg/day for children and 7 mg/day for adolescents; optimized   dose range: 0.05 to 0.12 mg/kg/day) and a 6-week dose maintenance period.   There were 526 patients included in the open-label phase. Among those, 315   patients  who  met  response  criteria  in  the  open-label  phase  were    then  randomized (1:1, guanfacine extended-release tablets: placebo) in a   26-week, double-blind, randomized withdrawal phase. The response criteria   were defined by ≥30% reduction in ADHD-RS-IV total score and a Clinical   Global Impression-Improvement (CGI-I) score of 1 or 2 during the open-label   phase. A statistically significantly lower proportion of treatment failures   occurred among guanfacine extended-release tablets  patients compared to   placebo at the end of the randomized withdrawal period (<linkHtml href="#ID148">Figure   4</linkHtml>). Treatment failure was defined as a ≥50% increase   (worsening) in ADHD-RS-IV total score and a ≥2-point increase in   Clinical Global Impression-Severity (CGI-S) score. Patients who met the   treatment failure criteria on two consecutive visits or discontinued for any   reason were classified as treatment failure.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 4.   Kaplan-Meier Estimation of Proportion of Patients with Treatment Failure for   Children and Adolescents Ages 6-17 (Study 7)</content>
                  </paragraph>
                  <paragraph/>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>Figure-04</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bc9cc5d2-e098-41da-ae90-0944715d6b92-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID117">
               <id root="8d17a661-f4e9-4cb3-9088-20d3e8b50eaa"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID118">Guanfacine extended-release tablets, USP 1 mg are white to   off-white, round shaped, biconvex tablets debossed with "41" on one   side of the tablet and "U" on other side. They are supplied as follows:</paragraph>
                  <paragraph>Bottles of 100s (NDC 29300-460-01)</paragraph>
                  <paragraph>Guanfacine extended-release tablets, USP 2 mg are white to   off-white, oval shaped, biconvex tablets debossed with "42" on one side   of the tablet and "U" on other side. They are supplied as follows:</paragraph>
                  <paragraph>Bottles of 100s (NDC 29300-461-01)</paragraph>
                  <paragraph>Guanfacine extended-release tablets, USP 3 mg are green to   light green slight mottled, round shaped, biconvex tablets debossed with "43"   on one side of the tablet and "U" on other side. They   are supplied as follows:</paragraph>
                  <paragraph>Bottles of 100s (NDC 29300-462-01)</paragraph>
                  <paragraph>Guanfacine extended-release tablets, USP 4 mg are green to light   green slight mottled, oval shaped, biconvex tablets debossed with "44"   on one side of the tablet and "U" on other side. They are supplied as follows:</paragraph>
                  <paragraph>Bottles of 100s (NDC 29300-463-01)</paragraph>
                  <paragraph>
                     <content styleCode="italics">Storage</content> - Store at 20°C to 25°C   (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).   See USP Controlled Room Temperature.</paragraph>
               </text>
               <effectiveTime value="20240906"/>
            </section>
         </component>
         <component>
            <section ID="ID119">
               <id root="26b1d4a8-4b2d-41ad-917c-615c580d94d2"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID120">Advise the patient to read the FDA-approved patient   labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Dosing and Administration </content>
                  </paragraph>
                  <paragraph>Instruct patients to swallow guanfacine   extended-release tablets whole with water, milk or other liquid. <content styleCode="underline">Tablets   should not be crushed, chewed or broken prior to administration because this   may increase the rate of release of the active drug.</content> Patients should not   take guanfacine extended-release tablets together with a high-fat meal, since   this can raise blood levels of guanfacine extended-release tablets. Instruct   the parent or caregiver to supervise the child or adolescent taking   guanfacine extended-release tablets and to keep the bottle of tablets out of   reach of children.</paragraph>
                  <paragraph>Advise patients not to abruptly discontinue guanfacine   extended-release tablets as abrupt discontinuation can result in clinically   significant rebound hypertension. Concomitant stimulant use and abrupt   discontinuation of guanfacine extended-release tablets may increase this   hypertensive response. Instruct patients on how to properly taper the dose to   minimize the risk of rebound hypertension <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID16">2.5</linkHtml>)   and Warnings and Precautions (<linkHtml href="#ID40">5.4</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Adverse   Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that sedation can occur, particularly early in   treatment or with dose increases. Caution against operating heavy equipment   or driving until they know how they respond to treatment with guanfacine   extended-release tablets <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID36">5.2</linkHtml>)].</content>   Headache and abdominal pain can also occur. If any of these symptoms persist,   or other symptoms occur, the patient should be advised to discuss the   symptoms with the health care provider.</paragraph>
                  <paragraph>Advise patients to avoid becoming dehydrated or overheated, which   may potentially increase the risks of hypotension and syncope <content styleCode="italics">[see   Warnings and Precautions (<linkHtml href="#ID34">5.1</linkHtml>)].</content> Advise patients   to avoid use with alcohol.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise breastfeeding mothers to monitor infants exposed to   guanfacine through breastmilk for sedation, lethargy and poor feeding <content styleCode="italics">[see   Use in Specific Populations (<linkHtml href="#ID76">8.2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>Trademarks are   the property of their respective owners.</paragraph>
                  <paragraph ID="ID139">
                     <content styleCode="bold">Patient Information </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Guanfacine (gwahn-fa-seen)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Extended-Release Tablets, USP </content>
                  </paragraph>
                  <paragraph>Read the Patient Information that comes with guanfacine extended-release tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are guanfacine extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Guanfacine extended-release tablets are prescription medicine used to treat the symptoms of attention deficit hyperactivity disorder (ADHD). Guanfacine extended-release tablets may be used alone or with ADHD stimulant medicines.</paragraph>
                  <paragraph>Guanfacine extended-release tablets are not a central nervous system (CNS) stimulant.</paragraph>
                  <paragraph>It is not known if guanfacine extended-release tablets are safe and effective in children younger than 6 years of age.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take guanfacine extended-release tablets</content>?</paragraph>
                  <paragraph>Do not take guanfacine extended-release tablets if you are allergic to guanfacine or any of the ingredients in guanfacine extended-release tablets. See the end of this leaflet for a complete list of ingredients in guanfacine extended-release tablets.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my doctor before taking guanfacine extended-release tablets? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before you take guanfacine extended-release tablets, tell your doctor if you:</content>
                  </paragraph>
                  <paragraph>●       have heart problems or a low heart rate</paragraph>
                  <paragraph>●         have fainted</paragraph>
                  <paragraph>●         have low or high blood pressure</paragraph>
                  <paragraph>●         have liver or kidney problems</paragraph>
                  <paragraph>●         have any other medical conditions</paragraph>
                  <paragraph>●         are pregnant or plan to become pregnant. It is not known if guanfacine extended-release tablets will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</paragraph>
                  <paragraph>●         are breastfeeding or plan to breastfeed. It is not known if guanfacine passes into your breast milk. Talk to your doctor about the best way to feed your baby while taking guanfacine extended-release tablets.</paragraph>
                  <paragraph>Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                  <paragraph>Guanfacine extended-release tablets may affect the way other medicines work, and other medicines may affect how guanfacine extended-release tablets works.</paragraph>
                  <paragraph>Especially tell your doctor if you take:</paragraph>
                  <paragraph>●  ketoconazole</paragraph>
                  <paragraph>●  medicines that can affect enzyme metabolism</paragraph>
                  <paragraph>●  high blood pressure medicine</paragraph>
                  <paragraph>●  sedatives</paragraph>
                  <paragraph>●  benzodiazepines</paragraph>
                  <paragraph>●  barbiturates</paragraph>
                  <paragraph>●  antipsychotics</paragraph>
                  <paragraph>Ask your doctor or pharmacist for a list of these medicines, if you are not sure.</paragraph>
                  <paragraph>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take guanfacine extended-release tablets?</content>
                  </paragraph>
                  <paragraph>●            Take guanfacine extended-release tablets exactly as your doctor tells you.</paragraph>
                  <paragraph>●            Your doctor may change your dose. Do not change your dose of guanfacine extended-release tablets without talking to your doctor.</paragraph>
                  <paragraph>●            Do not stop taking guanfacine extended-release tablets without talking to your doctor.</paragraph>
                  <paragraph>●            Try not to miss your dose of guanfacine extended-release tablets. If you miss a dose of guanfacine extended-release tablets take the next dose at your regular time. If you miss 2 or more doses, talk to your doctor, as you may need to restart guanfacine extended-release tablets with a lower dose.</paragraph>
                  <paragraph>●            Do not take a double dose to make up for a missed dose.</paragraph>
                  <paragraph>●            Guanfacine extended-release tablets should be taken 1 time a day in the morning or in the evening, either alone or in combination with an ADHD stimulant medicine that your doctor may prescribe. Your doctor will tell you when to take guanfacine extended-release tablets and when to take your ADHD stimulant medication.</paragraph>
                  <paragraph>●            Guanfacine extended-release tablets should be swallowed whole with a small amount of water, milk, or other liquid.</paragraph>
                  <paragraph>●            Do not crush, chew, or break guanfacine extended-release tablets. Tell your doctor if you cannot swallow guanfacine extended-release tablets whole.</paragraph>
                  <paragraph>●            Do not take guanfacine extended-release tablet with a high-fat meal.</paragraph>
                  <paragraph>●            Your doctor will check your blood pressure and heart rate while you take guanfacine extended-release tablets.</paragraph>
                  <paragraph>●            If you take too much guanfacine extended-release tablets, call your local Poison Control Center at 1-800-222-1222 or go to the nearest emergency room right away.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while taking guanfacine extended-release tablets?</content>
                  </paragraph>
                  <paragraph>●  Do not drive, operate heavy machinery, or do other dangerous activities until you know how guanfacine extended-release tablets affects you. Guanfacine extended-release tablets can slow your thinking and motor skills.</paragraph>
                  <paragraph>●  Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking guanfacine extended-release tablets until you talk with your doctor.</paragraph>
                  <paragraph>●  Guanfacine extended-release tablets taken with alcohol or medicines that cause sleepiness or dizziness may make your sleepiness or dizziness worse.</paragraph>
                  <paragraph>●  Do not become dehydrated or overheated. This may increase your chance of having low blood pressure or fainting while taking guanfacine extended-release tablets.</paragraph>
                  <paragraph>●  Do not suddenly stop guanfacine extended-release tablets. Tell your healthcare provider if you have been vomiting and cannot take guanfacine extended-release tablets, you may be at risk for rebound hypertension.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of guanfacine extended-release tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Guanfacine extended-release tablets may cause serious side effects including:</content>
                  </paragraph>
                  <paragraph>●  low blood pressure</paragraph>
                  <paragraph>●  low heart rate</paragraph>
                  <paragraph>●  fainting</paragraph>
                  <paragraph>●  sleepiness</paragraph>
                  <paragraph>●  increased blood pressure and heart rate after suddenly stopping guanfacine extended-release tablets (rebound hypertension). Suddenly stopping guanfacine extended-release tablets can cause increased blood pressure and heart rate and other withdrawal symptoms such as headache, confusion, nervousness, agitation, and tremors. If these symptoms continue to get worse and are left untreated, it could lead to a very serious condition including very high blood pressure, feeling very sleepy or tired, severe headache, vomiting, vision problems, seizures.</paragraph>
                  <paragraph>Get medical help right away, if you have any of the symptoms listed above.</paragraph>
                  <paragraph>
                     <content styleCode="bold">The most common side effects of guanfacine extended-release tablets include</content>:</paragraph>
                  <paragraph>●  sleepiness</paragraph>
                  <paragraph>●  tiredness</paragraph>
                  <paragraph>●  trouble sleeping</paragraph>
                  <paragraph>●  low blood pressure</paragraph>
                  <paragraph>●  nausea</paragraph>
                  <paragraph>●  stomach pain</paragraph>
                  <paragraph>●  dizziness</paragraph>
                  <paragraph>●  dry mouth</paragraph>
                  <paragraph>●  irritability</paragraph>
                  <paragraph>●  vomiting</paragraph>
                  <paragraph>●  slow heart rate</paragraph>
                  <paragraph>Tell the doctor if you have any side effect that bothers you or that does not go away.</paragraph>
                  <paragraph>These are not all the possible side effects of guanfacine extended-release tablets. For more information, ask your doctor or pharmacist.</paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store guanfacine extended-release tablets?</content>
                  </paragraph>
                  <paragraph>● Store guanfacine extended-release tablet between 68°F to 77°F (20°C to 25°C).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep guanfacine extended-release tablets and all medicines out of the reach of children. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General Information about the safe and effective use guanfacine extended-release tablets</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use guanfacine extended-release tablets for a condition for which it was not prescribed. Do not give guanfacine extended-release tablets to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                  <paragraph>This leaflet summarizes the most important information about guanfacine extended-release tablets. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about guanfacine extended-release tablets that is written for health professionals.</paragraph>
                  <paragraph>For more information, <content styleCode="bold">call Unichem Pharmaceuticals (USA), Inc. at 1-866-562-4616.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in Guanfacine extended-release tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredient</content>: guanfacine hydrochloride, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content> fumaric acid, glyceryl dibehenate, hypromellose, lactose monohydrate, methacrylic acid-ethyl acrylate copolymer, microcrystalline cellulose, polysorbate 80 and sodium lauryl sulfate. In addition, the 3 mg and 4 mg tablets also contain D &amp; C yellow #10 aluminium lake and FD &amp; C blue #1 aluminium lake.</paragraph>
                  <paragraph>Additional patient information leaflets can be obtained by calling Unichem at 1-866-562-4616.</paragraph>
                  <paragraph>
                     <content styleCode="bold">This Patient Information has been approved by the U.S. Food and Drug Administration.</content>
                  </paragraph>
                  <paragraph>Trademarks are the property of their respective owners.</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">UNICHEM LABORATORIES LTD.</content>
                  </paragraph>
                  <paragraph>Ind. Area, Meerut Road, Ghaziabad – 201003, India.</paragraph>
                  <paragraph>Manufactured For:</paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
                  <paragraph ID="ID122">East Brunswick, NJ 08816</paragraph>
                  <paragraph>02-R-12/2024</paragraph>
                  <paragraph>13015921</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bc9cc5d2-e098-41da-ae90-0944715d6b92-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID153">
               <id root="6e07cf45-5d20-4253-9bd4-ae93d4ead750"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <renderMultiMedia referencedObject="MM7">
                     <caption>1mg</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="MM8">
                     <caption>2mg</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="MM9">
                     <caption>3mg</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="MM10">
                     <caption>4mg</caption>
                  </renderMultiMedia>
               </text>
               <effectiveTime value="20241125"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>Guanfacine Extended-Release Tablets - 1mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bc9cc5d2-e098-41da-ae90-0944715d6b92-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Guanfacine Extended-Release Tablets - 2mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bc9cc5d2-e098-41da-ae90-0944715d6b92-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Guanfacine Extended-Release Tablets - 3mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bc9cc5d2-e098-41da-ae90-0944715d6b92-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Guanfacine Extended-Release Tablets - 4mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bc9cc5d2-e098-41da-ae90-0944715d6b92-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>